| Předmět: |
|
| Zdroj: |
Health & Medicine Week; 1/12/2024, p3883-3883, 1p |
| Abstrakt: |
A recent report from the Osaka Institute of Technology discusses the development of a new platform for evaluating the efficacy of medicinal treatments for muscle atrophy. The researchers highlight the importance of finding direct therapies for muscle atrophy, as current preventive measures such as diet and exercise are not definitive cures. The study introduces a versatile assay using an artificial skeletal muscle contractility-based drug quantification platform, which was shown to be effective in evaluating the efficacy of quercetin in enhancing muscle contractility and promoting myotube formation. This platform provides a bridge between cellular assays and human studies and has the potential to advance research into the treatment of muscle atrophy. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
